Full history for every metric is available with a Kvantra account

Stock profile
Vaxcyte, Inc. logo

Vaxcyte, Inc. (PCVX)

Country: United States of AmericaSector: HealthcareIndustry: BiotechnologyExchange: NASDAQ
P/E TTM
N/A
History
P/E NTM
N/A
Market cap
8.77B
Currency USD
KvantraRankAbout46
IValue51
IIQuality21
IIIMomentum72
Current price
55.39 USD-5.09%
Close 20 Nov 2026
Interval
Benchmarks

Key financial summary

Financials in USD
202020212022202320242025TTM2026E
Total revenue$m0.00.00.00.00.00.00.025.0
Operating profit$m-924-1,231
Net profit$m-89-100-223-402-464-767-1,148-1,090
EPS reported$-5.63-8.07
Operating cashflow per share$-4.82-8.34
Capex per share$0.100.23
FCF per share$-4.92-8.57
Free cash flow$m-669-1,276
Net debt$m-1,443-1,070
Book value equity$m2,6862,489
Book value per share$19.7316.72
Number of sharesm136.09148.91
DPS (TTM paid)$0.000.00

Financial summary

Financials in USD
202020212022202320242025TTM2026E
Value
P/E TTMx--
P/B LTMx2.343.52
P/S LTMx0.000.00
P/FCF LTMx-9.38-6.87
EV/EBITDA LTMx-8.39-6.80
EV/Sales LTMx0.000.00
Earnings Yield LTM%-12.21%-13.18%
FCF Yield%-10.66%-14.55%
Quality
ROE%-28.55%-42.04%
ROIC%-32.95%-45.41%
Operating margin%0.00%0.00%
Gross margin%0.00%0.00%
FCF/Sales%--
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%--
Net Income Growth YoY%--
FCF Growth%--
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%--
FCF/Debtx-5.70-5.75
Net Debt/EBITDAx0.08-0.09
EBIT/Net interestx--
Net debt/market cap%-22.99%-12.21%
Net debt/Equityx-0.54-0.43
Gross debt/equityx0.040.09

ETFs that hold Vaxcyte

FundTickerPosition#Weight
Global X - Russell 2000 ETFRSSL90.31%
ProShares Russell 2000 High Income ETFITWO100.28%

Funds with Vaxcyte among their ten largest holdings, largest fund first.

Price target estimates

Low estimate
High estimate
Price consensus
Last year average price target
Current price55.39 USD
Return Potential

Based on consensus from external analysts. Not Kvantra's opinion.

Ratings

Strong Buy
Buy
Hold
Sell
Strong Sell
Number of covering analysts

Based on consensus from external analysts. Not Kvantra's opinion.

ESG

Metric202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating

Company overview

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.

Trades inUSD

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Vaxcyte, Inc. (PCVX)

PCVX · NASDAQ · Healthcare
55.39 USD-5.09%
Sign up to track this stock
Benchmarks
KvantraRank46
Market cap8.77B
P/E NTMN/A
P/E TTMN/A
KvantraRank?46 / 100
Value
51
Quality
21
Momentum
72
Financialsin USD
20242025TTM2026E
ETFs that hold Vaxcyte
FundTickerPosition#Weight
Global X - Russell 2000 ETFRSSL90.31%
ProShares Russell 2000 High Income ETFITWO100.28%

Funds with Vaxcyte among their ten largest holdings, largest fund first.

Analyst target
Consensus
Current55.39 USD
Upside
Price consensus
Last year average price target
Current price55.39 USD
Return Potential

Consensus from external analysts. Not Kvantra's opinion.

Ratings
Strong Buy
Buy
Hold
Sell
Strong Sell

Based on consensus from external analysts. Not Kvantra's opinion.

ESG
202420252026
ESG-score
Environmental score
Social score
Governance score
Risk rating
About

Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.

IndustryBiotechnology
Trades inUSD

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free